MedPath

Effect of Cold Atmospheric Plasma on Malassezia Folliculitis

Not Applicable
Completed
Conditions
Malassezia Folliculitis
Interventions
Device: Cold atmospheric plasma treatment device
Registration Number
NCT04886323
Lead Sponsor
The Second Hospital of Anhui Medical University
Brief Summary

The cold atmospheric plasma may provide a new and effective method for the treatment of Malassezia folliculitis. The investigators conduct this randomized controlled trial to evaluate the effectiveness and safety of cold atmospheric plasma on Malassezia folliculitis. Participants entered this double-blind placebo-controlled trial will randomly assign to treatment with either cold atmospheric plasma or antifungal drugs. The differences of treatment effects of the two groups will be observed and compared.

Detailed Description

Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are limited due to adverse drug reactions and drug resistance. Cold atmospheric plasma has an inhibitory or killing effect on pathogenic microorganisms including fungi and has no obvious adverse damage to normal tissues. The investigators conduct this randomized controlled trial to study the effect of cold atmospheric plasma on Malassezia folliculitis, and evaluate its effectiveness and safety for Malassezia folliculitis. All data are recorded and compared after the end of the experiment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients are clinical presentation of Malassezia folliculitis in seborrheic areas.
  • The diagnoses are mycologically verified by experienced laboratory technicians.
  • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent.
Exclusion Criteria
  • Combined with other serious systemic diseases.
  • History of topical corticosteroids within 2 weeks or history of systemic corticosteroids within 1 month.
  • History of immunosuppressive drugs within 1 month.
  • History of topical antifungal medication within 2 weeks or systemic antifungal medication within 3 months.
  • Pregnant and lactating women.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
cold atmospheric plasma treatment groupCold atmospheric plasma treatment devicePatients are treated with a plasma device. Each treatment time was 3min per area based on the lesion size.The frequency of treatment is once a day. The duration of the treatment period is 2weeks.
Itraconazole capsules treatment groupItraconazole CapsulesPatients are treated with Itraconazole capsules, 200mg a day.The duration of the treatment period is 2weeks.
Primary Outcome Measures
NameTimeMethod
50% reduction in number of lesionweek 2

proportion of subjects who achieve at least a 50% reduction in total number of lesions

Secondary Outcome Measures
NameTimeMethod
proportion of subjects in physician's global assessment.week 2

proportion of subjects who achieve a physician's global assessment 0 / 1.

Trial Locations

Locations (1)

The Second Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath